Challenges in the Pharmaceutical Development of Very Low Concentration Dosage Forms for Highly Potent Immunotherapy Molecules

3/15/2021 14:40 - 15:15

  • Formulation to maintain safe, stable, low concentration dosing
  • Overcoming adsorption to ensure concentration consistency during DP manufacturing process
  • Ensuring safety and dose accuracy during preparation and clinical administration

Naila El Kechai, Formulation and Drug Product Team Leader, Sanofi